This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Say Nay to Northfield

Longtime readers might remember that I have a bit of an obsession with blood substitutes.

Remember, I'm the guy who spent three years -- and almost 80 stories -- detailing the myriad ways Biopure (BPUR) was misleading investors about its product Hemopure. I'm pretty proud of that work -- Biopure is now a penny stock, the Securities and Exchange Commission took successful action against the company, and the executives responsible for the wrongdoing were kicked out.

So, it's no surprise that I follow developments at Northfield Laboratories (NFLD) with great interest. Last month, the company's stock cratered after results from a pivotal phase III study revealed that trauma patients given its blood substitute Polyheme had a higher death rate than patients given a combination of saline and donated blood.

Needless to say, these were not the results that Northfield management and its supporters were hoping for. The $14 stock fell to the $4 level on the announcement. (Short-sellers, obviously, were a bit more jubilant.)

End of story, right? Not a chance. Northfield is forging ahead with plans to seek Food and Drug Administration approval for Polyheme later this year. On the company's quarterly conference call with investors Wednesday, CEO Steven Gould said the company was actually encouraged by the Polyheme data and is optimistic about its chances of success at the FDA.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs